CN1303941A - Human charcot-leyden crystal 3, its code sequence, preparation method and application - Google Patents

Abstract

The present invention provides the cDNA sequence of human Charcot-Leyden Crystal 3 (CLC3 for short), and the protein encoded by the cDNA is a homologue of human Charcot-Leyden crystal protein. The present invention also relates to polypeptides encoded by the nucleotide sequence, applications of these polynucleotides and polypeptides, and production methods of the polynucleotides and the polypeptides.

Description

People's Charcot Leyden crystals 3 and encoding sequence thereof, and method for making and purposes

The present invention relates to the genetically engineered field, particularly, the present invention relates to a kind of new human gene nucleotide sequence.More particularly, (Charcot-Leyden Crystal 3, cDNA sequence CLC3), this cDNA encoded protein are the proteic homologues of people's Charcot Leyden crystals to the present invention relates to people's Charcot Leyden crystals 3.The invention still further relates to by this nucleotide sequence coded polypeptide the application of these polynucleotide and polypeptide, and the production method of described polynucleotide and described polypeptide.

Charcot Leyden crystals (Charcot-Leyden Crystal, CLC) be that the bottom surface that nature is present in tissue and the secretory product is the bipyramid bodily form crystal of hexagonal, relevant with the oxyphie quantity increase in peripheral blood in parasitic processes, the supersensitivity process or the tissue.As far back as 1854, Charcot and Robin at first found Charcot Leyden crystals (Charcot, J.M. in the blood of corpse and leukaemic's spleen; Robin, C.:C.R.Seances Mem.Soc.Biol.Paris 5:44-52,1854), discovery (Leyden, E.Virchows Arch.Path.Anat.54:324-344,1872) was also also arranged in an asthma patient's saliva afterwards.

CLC is observed in the tissue of oxyphie related inflammation reaction and secretory product, these inflammatory reactions have (Beeson such as asthma, myelomatosis, anaphylaxis, parasitosis, P.B.1977 et al.The eosinopilIn Problems in the Internal Medicine, Vol.15.; Ottesen, E, A.et al 1978.The eosinophil, eosinophilia and eosinophil-related disorders.In Allergy:Principles and Practice, Vol.2.E.Middleton, C.E.Reed, and E.F.Ellis, eds.C.V.Mosby Co., St.Louis, MO, p.584.).CLC albumen accounts for about 10% (Weller of oxyphie total protein, P.F.et al.1984, J.Biol.Chem.259:15100), be the significant albumen of oxyphie, the bottom surface that identifies this uniqueness in body fluid and secretory product is the bipyramid bodily form crystal-CLC crystal of hexagonal, can be used as the sign of the relevant allergic inflammation of oxyphie.

The full length cDNA sequence of CLC obtains separation in 1993, the long 598bp of this cDNA sequence, the 142 amino acid whose polypeptide of encoding (Ackeman, S.J.et al 1993, J.Immun.150:456-468).The genome sequence of CLC is almost simultaneously obtained, the Dyer report is cloned into the genomic fragment that has comprised the CLC encoding sequence from No. 19 special karyomit(e) storehouses, cDNA and genome sequence analytical results to CLC show that the coded sequence of CLC forms (Dyer by 4 exon splicings, K.D.et al.1997, Genomics 40:17-221).

Mastrianni is positioned people's Charcot Leyden crystals albumen for No. 19 karyomit(e)s (Mastrianni, D.M.et al1991, Cytogenet.Cell Genet.58 2021).Fluorescence in situ hybridization technique with CLC further be positioned 19q13.1 (B.Trask and H.Morhrenweiser unpublished observation, cited in Ackeman, S.J.et al 1993, J.Immun.150:456-468).

Other has some experiments to show, Charcot Leyden crystals as one independently albumen have activity (Gleich, G.J.et al 1976, the J.Clin.Invest.57:633-640 of lysophospholipase; Weller, P.F.et al 1980, Proc.Nat.Acad.Sci.U.S.A.77; 7441-7443).This conclusion is also supported by some other experiment simultaneously: alkaline polyacrylamide gel electrophoresis showed, the dissolved Charcot Leyden crystals has only a band, and its molecular weight is 17400, conforms to the molecular weight of the lysophospholipase that is separated to from the acidophilia granulosa cell; In addition, acidophilia granulosa cell lysophospholipase can form the crystal of bicone, with the Charcot Leyden crystals homomorphosis.These show that all people's eosinophilic granulocyte lysophospholipase is moiety (Weller, P.F.et al 1980, the Proc.Nat.Acad.Sci.U.S.A.77 of Charcot Leyden crystals; 7441-7443).But CLC and other mammiferous lysophospholipase do not have structural similarity (Leonidas, D.D.et al.1995, Structure 3:1379-1393).

And some member of CLC albumen and Sugar receptors family has similarity on structure, partial function.The cDNA derivation albumen (Ackeman of CLC, S.J.et al 1993, J.Immun.150:456-468), structure (the Dyer of the intron-exon of genome order, K.D.et al.1997, Genomics 40:17-221), characteristic high conservative residue (Dyer, K.D.et al.1996, Life Sci.58:2073-2082), activity (Dyer in conjunction with sugar, K.D.et al.1996, Life Sci.58:2073-2082), one-piece construction (the Leonidas of crystallin, D.D.et al.1995, Structure 3:1379-1393) all similar to some member of galectin family, this shows that CLC albumen may have some relevant activity of galectin, at cell-cell, bring into play biological function (Dyer, K.D.et al.1997, Gemonics 40:217-221) by the beta galactose glycosides in conjunction with activity in the interaction of cell-matrix.

CLC is the sign of oxyphie, but in basophil CLC is arranged also.Submicroscopic structure studies show that, CLC is present in (Dvorak, A.M.et al.1988, Blood 72:150 in the particle of eosinophil and basophil; Dvorak, A, M.et al.1989, Lab.Invest.60:557).Recently, by immune technology for gold or indirect immunofluorescence location, find that also CLC is present in other positions in eosinophil and the basophil, as kytoplasm and nuclear (Dvorak, A.M.et al.1990, Lab.Invest.62:590-607; Dvorak, A.M.rtal.1991, Am.J.Pathol.138:69-82; Dvorak, A.M.et al.1997, Clin.Exp.Allergy 27:452-474), threshing passage, threshing channel membrane and the class particle similar of basophil to the primary granule of eosinophil.The variation that CLC albumen distributes shows that basophil inclusion (comprising CLC) has and discharges and the change procedure that obtains, and the function of CLC may relevant with the change procedure of its distribution (Dvorak, A.M.et al.1997, Clin.Exp.Allergy 27:452-474).

An object of the present invention is to provide a kind of new polynucleotide, these polynucleotide are named as people CLC3.

Another object of the present invention provides a kind of new people CLC3 albumen.

A further object of the present invention provides a kind of method of utilizing recombinant technology to produce described new people's CLC3 polypeptide.

The present invention also provides this people's the CLC3 nucleotide sequence and the application of polypeptide.

In one aspect of the invention, a kind of isolated dna molecular is provided, it comprises: coding has the nucleotide sequence of polypeptide of people CLC3 protein-active, shows at least 70% homology from the nucleotides sequence of Nucleotide 128-634 position among described nucleotide sequence and the SEQ ID NO.3 from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11; Perhaps described nucleotide sequence can be under the moderate stringent condition with SEQ ID NO.3 in from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11 from the nucleotide sequence hybridization of Nucleotide 128-634 position.Preferably, described sequence encoding one polypeptide, this polypeptide has the sequence shown in SEQ ID NO:4 or 12.More preferably, this sequence has among the SEQ ID NO.3 from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11 the nucleotide sequence from Nucleotide 128-634 position.

In another aspect of this invention, provide a kind of isolating people CLC3 protein polypeptide, it comprises: polypeptide or its conservative property variation polypeptide or its active fragments or its reactive derivative with SEQID NO:4 or 12 aminoacid sequences.Preferably, this polypeptide is to have SEQ ID NO:4 or 12 polypeptide of sequence.

In another aspect of this invention, provide a kind of carrier, it contains above-mentioned isolated DNA.

In another aspect of this invention, provide a kind of described carrier transformed host cells.

In another aspect of this invention, provide a kind of generation to have the method for the polypeptide of people CLC3 protein-active, this method comprises:

(a) nucleotide sequence that coding is had a polypeptide of people CLC3 protein-active operationally is connected in expression regulation sequence, form people CLC3 protein expression vector, from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11, show at least 70% homology among described nucleotide sequence and the SEQ ID NO.3 from the nucleotides sequence of Nucleotide 128-634 position;

(b) change the expression vector in the step (a) over to host cell, form the proteic reconstitution cell of people CLC3;

(c) under the condition that is fit to expressing human CLC3 protein polypeptide, the reconstitution cell in the culturing step (b);

(d) isolate polypeptide with people CLC3 protein-active.

In a specific embodiments of the present invention, isolating polynucleotide total length of the present invention is 530 Nucleotide, and its detailed sequence is seen SEQ ID NO:3, and wherein open reading frame is positioned at 28-447 position Nucleotide.Its encode a kind of people CLC3 albumen-be CLC3A albumen.In another specific embodiments of the present invention, isolating polynucleotide total length of the present invention is 717 Nucleotide, and its detailed sequence is seen SEQ ID NO:11, and wherein open reading frame is positioned at 128-634 position Nucleotide.Its encode another kind of people CLC3 albumen-be CLC3B albumen.CLC3A is the albumen that same gene is produced after different montages with CLC3B.

In the present invention, " isolating ", " purifying " or " pure substantially " DNA are meant, this DNA or fragment have been arranged in the sequence of its both sides and have separated under native state, refer to that also this DNA or fragment with under the native state follow the component of nucleic acid to separate, and separate with the protein of in cell, following it.

In the present invention, term " people CLC3 albumen (or polypeptide) encoding sequence " refer to the encode nucleotide sequence of polypeptide with people CLC3 protein-active, as among the SEQ ID NO.3 from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11 from the nucleotide sequence and the degenerate sequence thereof of Nucleotide 128-634 position.This degenerate sequence is meant, be arranged in the encoder block 28-447 position Nucleotide of SEQ ID NO:3 sequence or be arranged in the encoder block 128-634 position Nucleotide of SEQ ID NO:11 sequence, having one or more codons to be encoded, the degenerate codon of same amino acid replaces the back and the sequence that produces.Because the degeneracy of codon, thus with SEQ ID NO.3 in from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11, be low to moderate about 70% degenerate sequence also can encode out SEQ ID NO:4 or 12 described sequences from the nucleotide sequence homology of Nucleotide 128-634 position.This term also comprises can be under the moderate stringent condition, more preferably under the height stringent condition, with among the SEQ ID NO.3 from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11 from the nucleotide sequence of the nucleotide sequence hybridization of Nucleotide 128-634 position.Also term also comprise with SEQ ID NO.3 in from the nucleotide sequence of Nucleotide 28-447 position or SEQ IDNO.11 from the homology of nucleotide sequence at least 70% of Nucleotide 128-634 position, preferably at least 80%, at least 90% nucleotide sequence more preferably.

This term also comprises encoding to have and proteic, the SEQ ID NO:4 of people CLC3 identical function or the variant form of 12 sequences.These variant forms comprise (but being not limited to): disappearance, insertion and/or the replacement of several (be generally 1-90, preferably 1-60, more preferably 1-20,1-10 best) Nucleotide, and add several Nucleotide at 5 and/or 3 ends.Encoding sequence of the present invention can be DNA or RNA, can be strand or two strands.

In the present invention, " pure substantially " protein or polypeptide are meant that it accounts at least 20% of the total material of sample at least, preferably at least 50%, more preferably at least 80%, and at least 90% (by dry weight or weight in wet base) best.Purity can be measured with any suitable method, as measure the purity of polypeptide with column chromatography, PAGE or HPLC method.Substantially pure polypeptide is substantially free of the component of following it under the native state.

In the present invention, term " people CLC3 protein polypeptide " refers to have the SEQ IDNO:4 or 12 polypeptide of sequence of natural human CLC3 protein-active.This term also comprises having and variant forms people CLC3 identical function, SEQ ID NO:4 or 12 sequences.These variant forms comprise (but being not limited to): several (are generally 1-50, preferably 1-30, more preferably 1-20,1-10 best) amino acid whose disappearance, insertion and/or replacement, and add one or several at C-terminal and/or N-terminal and (be generally in 20, preferably being in 10, more preferably is in 5) amino acid.For example, in the art, when replacing, can not change proteinic function usually with the close or similar amino acid of performance.Again such as, add one or several amino acid at C-terminal and/or N-terminal and also can not change proteinic function usually.This term also comprises proteic active fragments of people CLC3 and reactive derivative.

The variant form of this polypeptide comprises: homologous sequence, conservative property varient, allelic variant, natural mutation, induced mutation body, under high or low tight degree condition can with the coded albumen of the DNA of people CLC3 DNA hybridization and the polypeptide or the albumen that utilize the antiserum(antisera) of anti-people CLC3 polypeptide to obtain.The present invention also provides other polypeptide, as comprises people CLC3 polypeptide or its segmental fusion rotein.Except the polypeptide of total length almost, the present invention has also comprised the soluble fragments of people CLC3 polypeptide.Usually, this fragment have people CLC3 peptide sequence at least about 10 continuous amino acids, usually at least about 30 continuous amino acids, preferably at least about 50 continuous amino acids, more preferably at least about 80 continuous amino acids, best at least about 100 continuous amino acids.

Invention also provides the analogue of people CLC3 albumen or polypeptide.The difference of these analogues and natural human CLC3 polypeptide can be the difference on the aminoacid sequence, also can be the difference that does not influence on the modified forms of sequence, perhaps haves both at the same time.These polypeptide comprise natural or the inductive genetic variant.The induce variation body can obtain by various technology, as by radiation or be exposed to mutagenic compound and produce random mutagenesis, also can pass through site-directed mutagenesis method or the biological technology of other known moleculars.Analogue also comprises having the analogue that is different from the amino acid whose residue of natural L-(as D-amino acid), and has non-natural analogue that exist or synthetic amino acid (as β, Y-amino acid).Should be understood that polypeptide of the present invention is not limited to the above-mentioned representational polypeptide that exemplifies.

(the not changing primary structure usually) form of modification comprises: the chemically derived form such as the acetylize or carboxylated of the polypeptide that body is interior or external.Modification also comprises glycosylation, carries out glycosylation modified and polypeptide that produce in the procedure of processing as those in the synthetic and processing of polypeptide or further.This modification can be carried out glycosylated enzyme (as mammiferous glycosylase or deglycosylating enzyme) and finishes by polypeptide is exposed to.Modified forms also comprises have the phosphorylated amino acid residue sequence of (as Tyrosine O-phosphate, phosphoserine, phosphothreonine).Thereby also comprise the polypeptide that has been improved its anti-proteolysis performance or optimized solubility property by modifying.

In the present invention, " people CLC3 conservative property variation polypeptide " refers to compare with the aminoacid sequence of SEQ ID NO.4 or 12, has 10 at the most, preferably at the most 8, more preferably at the most 5,3 amino acid is replaced by similar performance or close amino acid and is formed polypeptide at the most best.These conservative property variation polypeptide preferably carry out the amino acid replacement according to table 1 and produce.

Table 1

Initial residue	Representational replacement	The preferred replacement
			Ala(A)	Val；Leu；Ile	Val
Arg(R)	Lys；Gln；Asn	Lys
			Asn(N)	Gln；His；Lys；Arg	Gln

Asp(D)	Glu	Glu
			Cys(C)	Ser	Ser
Gln(Q)	Asn	Asn
			Glu(E)	Asp	Asp
Gly(G)	Pro；Ala	Ala
			His(H)	Asn；Gln；Lys；Arg	Arg
Ile(I)	Leu；Val；Met；Ala；Phe	Leu
			Leu(L)	Ile；Val；Met；Ala；Phe	Ile
Lys(K)	Arg；Gln；Asn	Arg
			Met(M)	Leu；Phe；Ile	Leu
Phe(F)	Leu；Val；Ile；Ala；Tyr	Leu
			Pro(P)	Ala	Ala
Ser(S)	Thr	Thr
			Thr(T)	Ser	Ser
Trp(W)	Tyr；Phe	Tyr
			Tyr(Y)	Trp；Phe；Thr；Ser	Phe
Val(V)	Ile；Leu；Met；Phe；Ala	Leu

The present invention also comprises people CLC3 polypeptid coding sequence and segmental antisense sequences thereof.This antisense sequences can be used for suppressing the expression of people CLC3 in the cell.

The present invention also comprises a kind of nucleic acid molecule that can be used as probe, and this molecule has 8-100 of people CLC3 polypeptid coding sequence, preferably 15-50 continuous nucleotide usually.This probe can be used for whether existing in the test sample nucleic acid molecule of coding people CLC3.

The present invention also comprises the method that detects people CLC3 nucleotide sequence, and it comprises with above-mentioned probe and sample and hybridizing whether detection probes combination has taken place then.Preferably, this sample is the product behind the pcr amplification, and wherein the pcr amplification primer is corresponding to the encoding sequence of people CLC3 polypeptide, and can be positioned at the both sides or the centre of this encoding sequence.Primer length is generally 15-50 Nucleotide.

In the present invention, can select various carrier known in the art for use, as commercially available carrier.Such as, select commercially available carrier for use, the nucleotide sequence with code book invention polypeptide operationally is connected in expression regulation sequence then, can form protein expression vector.

As used herein, " operationally being connected in " refers to a kind of like this situation, and promptly some part of linear DNA sequence can influence the activity of same other parts of linear DNA sequence.For example, if signal peptide DNA as precursor expression and participate in the secretion of polypeptide, signal peptide (secretion leader sequence) DNA operationally is connected in polypeptid DNA so; If transcribing of promotor control sequence, it is operationally to be connected in encoding sequence so; When if ribosome bind site is placed in the position that can make its translation, it is operationally to be connected in encoding sequence so.Generally, " operationally being connected in " means adjoining, then means in reading frame adjacent for the secretion leader sequence.

In the present invention, term " host cell " comprises prokaryotic cell prokaryocyte and eukaryotic cell.The example of prokaryotic host cell commonly used comprises intestinal bacteria, Bacillus subtilus etc.Eukaryotic host cell commonly used comprises yeast cell, insect cell and mammalian cell.Preferably, this host cell is an eukaryotic cell, as Chinese hamster ovary celI, COS cell etc.

On the other hand, the present invention also comprises people CLC3 DNA or the polypeptide of its fragment coding has specific polyclonal antibody and monoclonal antibody, especially monoclonal antibody.Here, " specificity " is meant that antibody capable is incorporated into people CLC3 gene product or fragment.Preferably, refer to that those can combine with people CLC3 gene product or fragment but nonrecognition and be incorporated into the antibody of other irrelevant antigen molecule.Among the present invention antibody comprise those can in conjunction with and suppress the proteic molecule of people CLC3, comprise that also those do not influence the antibody of people CLC3 protein function.The present invention also comprise those can with modify or without the people CLC3 gene product bonded antibody of modified forms.

The present invention not only comprises complete mono-clonal or polyclonal antibody, but also comprises having immunocompetent antibody fragment, as Fab ' or (Fab) 2 fragments; Heavy chain of antibody; Light chain of antibody; Genetically engineered strand Fv molecule (people such as Ladner, U.S. Patent No. 4,946,778); Or chimeric antibody, as have the murine antibody binding specificity but still keep antibody from people's antibody moiety.

Antibody of the present invention can be prepared by the known various technology of those skilled in that art.For example, the people CLC3 gene product of purifying or its have antigenic fragment, can be applied to animal to induce the generation of polyclonal antibody.Similarly, expressing human CLC3 or its have antigenic segmental cell and can be used to immune animal and produce antibody.Antibody of the present invention also can be monoclonal antibody.This type of monoclonal antibody can utilize hybridoma technology to prepare that (see people such as Kohler, Nature 256; 495,1975; People such as Kohler, Eur.J.Immunol.6:511,1976; People such as Kohler, Eur.J.Immunol.6:292,1976; People such as Hammerling, InMonoclonal Antibodies and T Cell-Hvbridomas.Elsevier, N.Y., 1981).Antibody of the present invention comprises the antibody that can block people CLC3 function and the antibody that does not influence people CLC3 function.Each antibody-like of the present invention can utilize the fragment or the functional zone of people CLC3 gene product, obtains by the routine immunization technology.These fragments or functional zone can utilize recombinant methods or utilize Peptide synthesizer synthetic.Can come immune animal and produce with the gene product of producing in the prokaryotic cell prokaryocyte (for example E.Coli) with the unmodified form bonded antibody of people CLC3 gene product; With posttranslational modification form bonded antibody (as the albumen or the polypeptide of glycosylation or phosphorylation), can come immune animal and obtain with the gene product that produces in the eukaryotic cell (for example yeast or insect cell).

People CLC3 Nucleotide full length sequence of the present invention or its fragment can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.

At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.

The proteic fragment of the present invention is except available recombination method produces, and also available solid phase technique is produced (people such as Stewart, (1969) Solid-Phase Peptide Synthesis, WH Freeman Co., San Francisco by direct peptide synthesis; Merrifield J. (1963) J.Am Chem.Soc 85:2149-2154).Can carry out by hand or automatically at external synthetic protein.For example, can (Foster City CA) synthesizes peptide automatically with the 431LA type peptide synthesizer of Applied Biosystems.Can distinguish proteic each fragment of chemosynthesis the present invention, be connected to produce the molecule of total length with chemical process then.

The proteic encoding sequence of the present invention also can be used for the assignment of genes gene mapping.For example,, the cDNA clone is hybridized with the karyomit(e) of metaphase, can carry out chromosomal localization exactly by fluorescence in situ hybridization technique (FISH).This technology can be used the cDNA that is as short as about 500bp; Also can use and grow to about 2000bp or longer cDNA.For this technology, can be referring to people such as Verma, Human Chromosomes:A Manual ofBasic Techniques, Pergamon Press, New York (1988).

In case sequence is located in certain exact position on the karyomit(e), the physical location of sequence on karyomit(e) can be associated with the genetic map data.These genetic map data can obtain, for example by Mendelian (Mendelian) people genetic database (can obtain on the net by Johns Hopkins University Welch MedicalLibrary).Then, come identified gene by linkage analysis and be positioned dependency between the disease of same chromosomal region.

Then, be necessary to determine the cDNA between diseased individuals and the healthy individual or the difference of genome sequence aspect.Be not present in normal individual if a certain sudden change is present in part or all of diseased individuals, this sudden change may be exactly the paathogenic factor of this disease so.

Utilize albumen of the present invention,, can filter out with CLC3 interactional material takes place, as acceptor, inhibitor or antagonist etc. by various conventional screening methods.

Albumen of the present invention and antibody thereof, inhibitor, antagonist or acceptor etc. when using (administration) in treatment, can provide different effects.Usually, can these materials are formulated in nontoxic, inert and the pharmaceutically acceptable aqueous carrier medium, wherein pH is about 5-8 usually, and preferably pH is about 6-8, although the pH value can be with being changed to some extent by preparation Substance Properties and illness to be treated.The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, subcutaneous, intracutaneous or topical.

With people CLC3 albumen of the present invention is example, can be with itself and suitable pharmaceutically acceptable carrier coupling.This class pharmaceutical composition contains protein and the pharmaceutically acceptable carrier or the vehicle for the treatment of significant quantity.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.People CLC3 albumen of the present invention can be made into the injection form, for example is prepared by ordinary method with the physiological saline or the aqueous solution that contains glucose and other assistant agents.Pharmaceutical composition such as tablet and capsule can be prepared by ordinary method.Pharmaceutical composition such as injection, solution, tablet and capsule should be made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity, for example every day about 1 microgram/kg body weight-Yue 5 mg/kg body weight.In addition, polypeptide of the present invention also can use with the other treatment agent.

When people CLC3 protein polypeptide of the present invention is used as medicine, this polypeptide of treatment effective dose can be applied to Mammals, wherein should treat effective dose usually at least about 10 micrograms/kg body weight, and in most of the cases be no more than about 8 mg/kg body weight, preferably this dosage is about 10 micrograms/kg body weight-Yue 1 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.

The reaction of CLC and oxyphie related inflammation has confidential relation, and it can be used as the sign of the relevant allergic inflammation of oxyphie in body fluid and the evaluation in the secretory product.In addition, CLC shows that in the similarity of structure, partial function CLC albumen may have some relevant activity of Sugar receptors with some member of Sugar receptors family, at cell-cell, bring into play biological function (Dyer by the beta galactose glycosides in conjunction with activity in the interaction of cell-matrix, K.D.et al.1997, Gemonics 40:217-221).CLC also is present in the basophil, its vicissitudinous process that distributes, and the function of CLC may relevant with the change procedure of its distribution (Dvorak, A.M.et al.1997, Clin.Exp.Allergy 27:452-474).

In addition, because people CLC3 of the present invention has the natural acid sequence that is derived from the people, therefore, compare, estimate to have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to man-hour with the albumen of the same clan that derives from other species.

In the accompanying drawings, Fig. 1 is people CLC3A of the present invention, CLC3B and people CLC (hCLC), mouse CLC (mCLC) and orangutan CLC 5 kinds of proteic amino acid sequence homologous comparison diagrams such as (pCLC).Wherein, identical amino acid marks with " * " below sequence, and similar amino acid marks with " ".

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.

Embodiment 1

The clone and the mensuration of the cDNA sequence of people CLC3A

(A) clone and the mensuration of the cDNA sequence of people CLC3A

1. primer amplification

With human brain λ gtllcDNA library (available from Clontech company) is template, with a pair of oligonucleotide is primer--A:5 '-TGAAGAACTACACAGAGGGAGAC-3 ' (SEQ ID NO:1) is a forward primer, oligonucleotide B:5 '-GATCGTTCTGTTAGCAGGCTCTG-3 ' (SEQ ID NO:2) is a reverse primer, carries out PCR.The PCR condition be 93 ℃ 4 minutes, carried out 35 circulations in 1 minute with 93 ℃ 1 minute, 64 ℃ 1 minute and 72 ℃ thereupon, last 72 ℃ were extended 5 minutes.The PCR segment that electrophoresis detection obtains is about the purpose fragment of 550bp.

2.PCR the order-checking of product

Above-mentioned pcr amplification product A/B is connected with pGEM-T carrier (Promega), transformed into escherichia coli JM103, extract plasmid with QIAprep Plasmid test kit (QIAGEN), check order to inserting fragment with SequiThermEXCELTMDNA sequencing kit (Epicentre Technologies), with computer software splicing order, obtain full length cDNA sequence at last, altogether 530bp, detailed sequence is seen SEQ ID NO:3, and wherein open reading frame is positioned at 28-447 position Nucleotide.

Derive the aminoacid sequence of people CLC3A according to the full length cDNA sequence that obtains, totally 139 amino-acid residues, its aminoacid sequence sees SEQ ID NO:4 for details.

(B) clone and the mensuration of the cDNA sequence of people CLC3B

Adopt identical method with clone CLC3A, difference only is: used a pair of Oligonucleolide primers difference, be about to oligonucleotide A ': 5 '-ACAGTGAGCTGTGACCATGCCAC-3 ' (SEQ ID NO:9) is a forward primer, oligonucleotide B ': 5 '-GATCGTTCTGTTAGCAGGCTCTG-3 ' (SEQ ID NO:10) is a reverse primer, carries out PCR.The PCR segment that electrophoresis detection obtains is about the purpose fragment of 700bp.

2.PCR the order-checking of product

With above-mentioned pcr amplification product A '/B ' and pGEM-T ^Carrier (Promega) connects, and transformed into escherichia coli JMl03 extracts plasmid with QIAprep Plasmid test kit (QIAGEN), uses SequiThermEXCEL ^TMDna sequencing kit (Epicentre Technologies) checks order to inserting fragment, with computer software splicing order, obtain full length cDNA sequence at last, altogether 717bp, detailed sequence is seen SEQ ID NO:11, and wherein open reading frame is positioned at 128-634 position Nucleotide.

Derive the aminoacid sequence of people CLC3B according to the full length cDNA sequence that obtains, totally 168 amino-acid residues, its aminoacid sequence sees SEQ ID NO:12 for details.

Embodiment 2

Homology relatively

Full length cDNA sequence and proteins encoded thereof with people CLC3 of the present invention, in Non-redundantGenBank+ EMBL+DDBJ+PDB database and Non-redundant GenBank CDStranslations+PDB+SwissProt+Spupdate+PIR database, carry out nucleic acid and albumen homology retrieval with blast program.Found that the CLC (gb|L01664) with the people on nucleotide level and protein level has higher homology.Wherein, CLC3A albumen and the proteic identity of people CLC reach 63%, and similarity reaches 70%.CLC3B derivation albumen and the proteic identity of people CLC reach 61%, and similarity reaches 68%.In addition, the CLC partial sequence of having announced in CLC3A and CLC3B and mouse and the orangutan has also shown higher homology (amino acid sequence homologous of CLC3A and CLC3B and hCLC, mCLC and pCLC is relatively seen Fig. 1).

In addition, CLC3A and CLC3B albumen much at one, difference only is: CLC3B has had more 29 amino acid (Fig. 1) at N end.Therefore, this hint CLC3A and CLC3B are the different montages bases of same gene.

According to the structures shape function, the Biological Principles that the structural similitude function is relevant can be inferred the biological function of CLC3 of the present invention according to the function of CLC gene in the known different plant species and proteins encoded thereof.

CLC observes in the tissue of oxyphie related inflammation reaction and secretory product, these inflammatory reactions have asthma, myeloid leukemia, anaphylaxis, (Beeson such as parasitosis, P.B.1977 et al.The eosinopil InProblems in the Internal Medicine, Vol.15.; Ottesen, E, A.et al 1978.The eosinophil, eosinophilia and eosinophil-related disorders.In Allergy:Principles and Practice, Vol.2.E.Middleton, C.E.Reed, and E.F.Ellis, eds.C.V.Mosby Co., St.Louis, MO, p.584.).CLC albumen accounts for about 10% (Weller of oxyphie total protein, P.F.et al.1984, J.Biol.Chem.259:15100), be the significant albumen of oxyphie, the bottom surface that identifies this uniqueness in body fluid and secretory product is the bipyramid bodily form crystal-CLC crystal of hexagonal, can be used as the sign of the relevant allergic inflammation of oxyphie.

And there is the similarity on structure, the partial function in some member of CLC albumen and Sugar receptors family.The cDNA derivation albumen of CLC and the member who combines beta galactose glycosides S-sample animal Sugar receptors (galectin) superfamily have similarity (Ackeman, S.J.et al 1993, J.Immun.150:456-468).The structure of the intron-exon of CLC genome order and the structural similitude of galectin, all beta galactose glycosides binding site is by an exon-coding, this feature be consistent with all so far galectin (Dyer, K.D.et al.1997, Genomics 40:17-221).

The sequential analysis of protein of CLC albumen and people galectin shows, CLC3A albumen has 10 in distinctive 13 high conservative residues of this family, and they are the 24th G, the 53rd H, the 55th R (similar to the N of galectin family corresponding position), the 63rd V, the 65th N, the 72nd W, the 75th E, the 83rd F, the 86th G and the 115th R.CLC3B albumen has 10 in distinctive 13 high conservative residues of this family, and they are the 53rd G, the 82nd H, the 84th R (similar to the N of galectin corresponding position), the 92nd V, the 94th N, the 101st W, the 104th E, the 112nd F, the 115th G and the 144th R.

CLC albumen can be incorporated into the agarose resin of coupling lactose, and this keying action also depends on the dosage (Dyer, K.D.et al.1996, Life Sci.58:2073-2082) of sugar.X-ray crystalline diffraction shows that the one-piece construction of CLC crystallin is highly similar with-2 to galectin-1.CLC contains most of residue (Leonidas, D.D.et al.1995, Structure 3:1379-1393) in the carbohydrate recognition structure territory of conservative galectin.These results show that CLC albumen may have some relevant activity of Sugar receptors, may be at cell-cell, bring into play biological function (Dyer, K.D.et al.1997, Gemonics 40:217-221) by the beta galactose glycosides in conjunction with activity in the interaction of cell-matrix.

CLC is the sign of oxyphie, but in basophil CLC is arranged also.Submicroscopic structure studies show that, CLC is present in (Dvorak, A.M.et al.1988, Blood 72:150 in the particle of eosinophil and basophil; Dvorak, A, M.et al.1989, Lab.Invest.60:557).Recently, by immune technology for gold or indirect immunofluorescence location, find that also CLC is present in other positions in eosinophil and the basophil, as kytoplasm and nuclear (Dvorak, A.M.et al.1990, Lab.Invest.62:590-607; Dvorak, A.M.rtal.1991, Am.J.Pathol.138:69-82; Dvorak, A.M.et al.1997, Clin.Exp.Allergy 27:452-474), threshing passage, threshing channel membrane and the class particle similar of basophil to the primary granule of eosinophil.The variation that CLC albumen distributes shows that basophil inclusion (comprising CLC) has to discharge with the process that obtains and changes, and the function of CLC may relevant with the change procedure of its distribution (Dvorak, A.M.et a1.1997, Clin.Exp.Allergy 27:452-474).

People CLC3 of the present invention is used for further functional study except can be used as this family's a member, also can be used for producing fusion rotein with other albumen, such as producing fusion rotein with immunoglobulin (Ig).In addition, inventor CLC3 can also merge with other members of this family or exchange fragment, to produce new albumen.For example the N end of inventor CLC3 and the N end of mouse CLC are exchanged, to produce the albumen that new activity is higher or have new features.

People CLC3 of the present invention also can be used for screening antagonist that suppresses protein-active of the present invention or the agonist that strengthens protein-active of the present invention etc.

At the antibody of inventor CLC3, be used to screen other members of this family, perhaps be used for affinity purification associated protein (as other members of this family).

In addition, inventor CLC3 nucleic acid (encoding sequence or antisense sequences) can be by the cell that induces one, with expression level that improves people CLC3 or the overexpression that suppresses people CLC3.People CLC3 albumen of the present invention or its active polypeptide fragment can be applied to patient, with treatment or alleviate because of people CLC3 disappearance, no function or unusual cause related disorders arranged.In addition, can also be with carrying out relevant diagnosis or prognosis judgement based on nucleotide sequence of the present invention or antibody.

Embodiment 3

(A) expression of people CLC3A in intestinal bacteria

In this embodiment, with pcr amplification product A/B among the embodiment 1 is template, with the cDNA sequence of coding people CLC3A use corresponding to 5 of this dna sequence dna ' and the PCR Oligonucleolide primers (SEQ ID NO:5 and 6) of 3 ' end increase, obtain people CLC3A cDNA as inserting fragment.

5 ' Oligonucleolide primers sequence of using in the PCR reaction is:

5-CAAGGTCGACATGTCATCACTAAAAGTAC-3 ' (SEQ ID NO:5), this primer contains the restriction enzyme site of Sal I restriction enzyme, is 19 Nucleotide of the people CLC3A encoding sequence that begun by initiator codon after this restriction enzyme site;

3 ' end primer sequence is:

5-TAGGAAGCTTTCAATTACAGACAGACACT-3 (SEQ ID NO:6), this primer contains the part encoding sequence of restriction enzyme site, translation termination and the people CLC3A of Hind III restriction enzyme.

The restriction enzyme site of the restriction enzyme on the primer is corresponding to bacterial expression vector pQE-9 (Qiagen Inc., Chatsworth, the CA) restriction enzyme digestion sites on, this plasmid vector coding antibiotics resistance (Amp ^r), a bacterium replication orgin (ori), an adjustable promotor/operon of IPTG-(P/O), a ribosome bind site (RBS), a 6-histidine mark thing (6-His) and restriction enzyme cloning site.

With Sal I and Hind III digestion pQE-9 carrier and insertion fragment, will insert fragment subsequently and be connected to the pQE-9 carrier and keep open reading frame initial at bacterium RBS.Transform available from Qiagen with connecting mixture subsequently, the E.coli bacterial strain of commodity M15/rep4 by name, M15/rep4 contains the plasmid pREP4 of multiple copied, and it is expressed lac I repressor and carries kalamycin resistance (Kanr).Screen transformant containing on the LB culture dish of Amp and Kan, the extracting plasmid, the cDNA fragment of sequence verification people CLC3A has correctly been inserted carrier.

Incubated overnight (O/N) contains the positive transformant clone of required construction in the LB liquid nutrient medium of adding Amp (100 μ g/ml) and Kan (25 μ g/ml).Spend the night (O/N) culture with 1: 100-1: 250 thinning ratio dilution, be inoculated into then in the large volume substratum, culturing cell grows to 600 optical density(OD) (OD ₆₀₀) when being 0.4-0.6, add IPTG (" isopropylthio-") to final concentration be 1mM.By making lac I repressor inactivation, IPTG induces startup P/O to cause gene expression dose to improve.Continued culturing cell 3-4 hour, centrifugal subsequently (6000 * g, 20 minutes).The ultrasonic degradation culture, the collecting cell lysate also is diluted in it in 6M Guanidinium hydrochloride.After the clarification, by containing under the condition that 6-His marker albumen combines closely making, with nickel-chelate column chromatography purifying dissolved people CLC3A from solution.With 6M Guanidinium hydrochloride (pH5.0) wash-out people CLC3A from post.Available several method is the sex change protein precipitation from Guanidinium hydrochloride.Perhaps, use the dialysis step to remove Guanidinium hydrochloride, perhaps isolated purifying protein from nickel-chelate column.Protein behind the purifying is incorporated in second post, has the linear Guanidinium hydrochloride gradient of successively decreasing in this post.Protein denaturation when being attached to this post is used Guanidinium hydrochloride (pH5.0) wash-out subsequently.At last, soluble protein is dialysed with PBS, then protein is kept in the stock solution that final concentration is 10% (w/v) glycerine.

SDS-PAGE glue with 12% carries out electrophoresis, identifies that the molecular weight size of expressing protein is about 16kDa.

In addition, the amino acid that reaches proteic N end and each 10 amino acid length of C end is checked order, find consistent with the sequence of SEQ ID NO:4 with ordinary method.

(B) expression of people CLC3B in intestinal bacteria

Adopt the program identical that people CLC3B is expressed with embodiment 3 (A), difference only is: with pcr amplification product A '/B ' among the embodiment 1 is template, use cDNA sequence 5 corresponding to people CLC3B ' and the PCR Oligonucleolide primers (SEQ ID NO.13 and 6) of 3 ' end replace the primer shown in the SEQ ID NO:5 and 6.

5 ' Oligonucleolide primers sequence of using in the PCR reaction is:

5-CAAGGTCGACATGACTTCCCTGGCCCACAC-3 ' (SEQ ID NO:13), this primer contains the restriction enzyme site of Sal I restriction enzyme, is 20 Nucleotide of the people CLC3B encoding sequence that begun by initiator codon after this restriction enzyme site;

3 ' end primer sequence is:

5-TAGGAAGCTTTCAATTACAGACAGACACT-3 (SEQ ID NO:6), this primer contains the part encoding sequence of restriction enzyme site, translation termination and the people CLC3B of Hind III restriction enzyme.

Subsequently, with Sal I and Hind III digestion pQE-9 carrier and insertion fragment, will insert fragment subsequently and be connected to the pQE-9 carrier and keep open reading frame initial at bacterium RBS.Transform available from Qiagen the E.coli bacterial strain of commodity M15/rep4 by name with connecting mixture subsequently.Screen transformant containing on the LB culture dish of Amp and Kan, the extracting plasmid, the cDNA fragment of sequence verification people CLC3B has correctly been inserted carrier.

The expressing protein that obtains carries out electrophoresis with 12% SDS-PAGE glue, identifies that the molecular weight size of expressing protein is about 19kDa.Check order with the amino acid of ordinary method, find consistent with the sequence of SEQ ID NO.12 to the proteic N end of people CLC3B and each 10 amino acid length of C end.

Embodiment 4

(A) expression of people CLC3A in eukaryotic cell (Chinese hamster ovary celI strain)

In this embodiment, with pcr amplification product A/B among the embodiment 1 is template, with the cDNA sequence of coding people CLC3A use corresponding to 5 of this dna sequence dna ' and the PCR Oligonucleolide primers (SEQ ID NO:7 and 8) of 3 ' end increase, obtain people CLC3A cDNA as inserting fragment.

5 ' Oligonucleolide primers sequence of using in the PCR reaction is:

5 '-this primer of CAAGAAGCTTATGTCATCACTAAAAGTAC-3 ' (SEQ ID NO:7) contains the restriction enzyme site of Hind III restriction enzyme, is 19 Nucleotide of the people CLC3A encoding sequence that begun by initiator codon after this restriction enzyme site;

3 ' end primer sequence is:

This primer of 5-TAGGGGATCCTCAATTACAGACAGACACT-3 (SEQ ID NO:8) contains the part encoding sequence of the restriction enzyme site of BamH I restriction enzyme, translation termination and people CLC3A.

The restriction enzyme site of the restriction enzyme on the primer is corresponding to the restriction enzyme digestion sites on the expressing cho cell carrier pcDNA3, and this plasmid vector coding antibiotics resistance (Ampr and Neor), a phage replication starting point (flori), a virus replication starting point (SV40 ori), T7 promotor, a viral promotors (P-CMV), a Sp6 promotor, a SV40 promotor, a SV40 tailing signal and corresponding polyA order, a BGH tailing signal and a corresponding polyA are in proper order.

With Hind III and BamH I digestion pcDNA3 carrier and insertion fragment, will insert fragment subsequently and be connected to the pcDNA3 carrier.Subsequently with connecting mixture Transformed E .coli DH5 α bacterial strain.Screen transformant containing on the LB culture dish of Amp, incubated overnight (O/N) contains the clone of required construction in the LB liquid nutrient medium of adding Amp (100 μ g/ml).The extracting plasmid, the cDNA fragment of sequence verification people CLC3A has correctly been inserted carrier.

The plasmid transfection Chinese hamster ovary celI is to adopt lipofection, carries out with Lipofectin (GiBco Life).After the transfection 48 hours, through the lasting G418 pressurization screening in 2-3 week, collecting cell and cell conditioned medium are measured the expressing protein enzyme activity.Remove G418, continuous passage is cultivated; To mixing the clone cell Method of Limited Dilution, select to have the cell subclone of higher protein-active.The above-mentioned positive subclone of a large amount of according to a conventional method cultivations.After 48 hours, beginning collecting cell and supernatant are with ultrasonic degradation method smudge cells.With 50mM Tris.HCl (pH7.6) solution that contains 0.05%Triton is balance liquid and elutriant, uses through the Superdex of pre-equilibration G-75 post and collects above-mentioned proteic active peak.Using 50mMTris.HCl (pH8.0) equilibrated DEAE-Sepharose post again, is that elutriant carries out gradient elution with 50mMTris.HCl (pH8.0) solution that contains 0-1M NaCl, collects above-mentioned proteic active peak.Be that dialyzate is dialysed to expressing protein solution with PBS (pH7.4) then.Last freeze-drying is preserved.

SDS-PAGE glue with 12% carries out electrophoresis, identifies that the molecular weight size of expressing protein is 16kDa.

In addition, the amino acid that reaches proteic N end and each 10 amino acid length of C end is checked order, find consistent with the sequence of SEQ ID NO:4 with ordinary method.

(B) expression of people CLC3B in eukaryotic cell (Chinese hamster ovary celI strain)

Adopt the program identical that people CLC3B is expressed with embodiment 4 (A), difference only is: with pcr amplification product A '/B ' among the embodiment 1 is template, use cDNA sequence 5 corresponding to people CLC3B ' and the PCR Oligonucleolide primers (SEQ ID NO.14 and 8) of 3 ＇ end replace the primer shown in the SEQ ID NO:7 and 8.

5 ' Oligonucleolide primers sequence of using in the PCR reaction is:

5 '-this primer of CAAGAAGCTTATGACTTCCCTGGCCCACAC-3 ' (SEQ ID NO:14) contains the restriction enzyme site of Hind III restriction enzyme, is 19 Nucleotide of the people CLC3B encoding sequence that begun by initiator codon after this restriction enzyme site;

3 ' end primer sequence is:

This primer of 5-TAGGGGATCCTCAATTACAGACAGACACT-3 (SEQ ID NO:8) contains the part encoding sequence of the restriction enzyme site of BamH I restriction enzyme, translation termination and people CLC3B.

Subsequently, with Hind III and BamH I digestion pcDNA3 carrier and insertion fragment, will insert fragment subsequently and be connected to the pcDNA3 carrier.Subsequently with connecting mixture Transformed E .coli DH5 α bacterial strain.As mentioned above, screen transformant containing on the LB culture dish of Amp, incubated overnight (O/N) contains the clone of required construction in the LB liquid nutrient medium of adding Amp (100 μ g/ml).The extracting plasmid, the cDNA fragment of sequence verification people CLC3B has correctly been inserted carrier.

As above use plasmid transfection Chinese hamster ovary celI, expressing protein and separation and purification.The albumen that obtains carries out electrophoresis with 12% SDS-PAGE glue, identifies that the molecular weight size of expressing protein is 19kDa.Check order with the amino acid of ordinary method, find consistent with the sequence of SEQ ID NO.12 to the proteic N end of people CLC3B and each 10 amino acid length of C end.

Embodiment 5

Preparation antibody

With CLC3A and the CLC3B recombinant protein that obtains in embodiment 3 and 4, be used for immune animal respectively to produce antibody, concrete grammar is as follows.Recombinant molecule is standby after separating with chromatography.Also available SDS-PAGE gel electrophoresis separates, electrophoretic band downcut from gel, and with isopyknic complete Freund s adjuvant emulsion.Albumen with 50-100 μ g/0.2ml emulsification carries out peritoneal injection to mouse.After 14 days,, mouse is carried out peritoneal injection with booster immunization with the dosage of 50-100 μ g/0.2ml with the same antigen of non-complete Freund ' s adjuvant emulsion.Carried out booster immunization one time every 14 days, carry out at least three times.The sero-fast specific reaction that obtains is active to be assessed in the ability of external precipitation people CLC3 gene translation product with it.Found that antibody can precipitate with albumen of the present invention specifically.

All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Sequence table (1) general information: (ⅰ) applicant: Fudan University (ⅱ) denomination of invention: people's Charcot Leyden crystals 3 and encoding sequence thereof, and method for making and purposes (ⅲ) sequence number: information (ⅰ) sequence signature of 14 (2) SEQ ID NO:1

(A) length: 23 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:1:TGAAGAACTA CACAGAGGGA GAC 23 (2) SEQ ID NO:2

(A) length: 23 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:2GATCGTTCTG TTAGCAGGCT CTG 23 (2) SEQ ID NO:3: (ⅰ) sequence signature:

(A) length: 530bp

(B) type: nucleic acid

(C) chain: two strands

( D ) ： ( ⅱ ) ：cDNA ( ⅹⅰ ) ：SEQ ID NO:3TGAAGAACTA CACAGAGGGA GACAACAATG TCATCACTAA AAGTACCACA CACACGGCCT 60GTGTCCTTGT CTACTGGTTC TTGTGTGATA ATCACAGGGA CACCGATCAT CCCTTTCGTC 120ATGGACCCAC AGCTGCAGGT GGATTTCCAT ACCGAGATGA AGGAAGACTC AGACATCGCC 180TTCCATTTCC GAGTGTACTT TGGTCATTGG GTGGTCATGA ACAGCCGCGT GAATGGGGCT 240TGGCAGTATG AGGTGACATG CCACAATATG CCCTTTCAGG ATGGTAAACC ATTTAACCTG 300TGCATCTCCG TGCTGGCCGA TGAGTACCAG GTAATGGTAA ATGGCCAAAA TGCTTACAGC 360TTTCCCCACC GACTCCCACC ATCTTATGTG AAGATGGTGC AAGTGTGGAG AGATGTCTCC 420CTGACCTCAG TGTCTGTCTG TAATTGATGA AATGATCACA TTCCTCATGG TTAAAGAATC 480CCTGTTTCTG TGCGACCATG GCATTTCCAG AGCCTGCTAA CAGAACGATC 530 ( 2 ) SEQ ID NO:4： ( ⅰ ) ：

(A) length: 139 amino acid

(B) type: amino acid

( D ) ： ( ⅱ ) ： ( ⅹⅰ ) ：SEQ ID NO:4Met Ser Ser Leu Lys Val Pro His Thr Arg Pro Val Ser Leu Ser 15Thr Gly Ser Cys Val Ile Ile Thr Gly Thr Pro Ile Ile Pro Phe 30Val Met Asp Pro Gln Leu Gln Val Asp Phe His Thr Glu Met Lys 45Glu Asp Ser Asp Ile Ala Phe His Phe Arg Val Tyr Phe Gly His 60Trp Val Val Met Asn Ser Arg Val Asn Gly Ala Trp Gln Tyr Glu 75Val Thr Cys His Asn Met Pro Phe Gln Asp Gly Lys Pro Phe Asn 90Leu Cys Ile Ser Val Leu Ala Asp Glu Tyr Gln Val Met Val Asn 105Gly Gln Asn Ala Tyr Ser Phe Pro His Arg Leu Pro Pro Ser Tyr 120Val Lys Met Val Gln Val Trp Arg Asp Val Ser Leu Thr Ser Val 135Ser Val Cys Asn 139 ( 2 ) SEQ ID NO:5 ( ⅰ )

(A) length: 29 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:5:CAAGGTCGAC ATGTCATCAC TAAAAGTAC 29 (2) SEQ ID NO:6

(A) length: 29 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:6:TAGGAAGCTT TCAATTACAG ACAGACACT 29 (2) SEQ ID NO:7

(A) length: 29 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:7CAAGAAGCTT ATGTCATCAC TAAAAGTAC 29 (2) SEQ ID NO:8

(A) length: 29 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:8TAGGGGATCC TCAATTACAG ACAGACACT 29 (2) SEQ ID NO:9

(A) length: 23 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:9:ACAGTGAGCT GTGACCATGC CAC 23 (2) SEQ ID NO:10

(A) length: 23 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:10GATCGTTCTG TTAGCAGGCT CTG 23 (2) SEQ ID NO:11: (ⅰ) sequence signature:

(A) length: 717bp

(B) type: nucleic acid

(C) chain: two strands

( D ) ： ( ⅱ ) ：cDNA ( ⅹⅰ ) ：SEQ ID NO:11ACAGTGAGCT GTGACCATGC CACTGCAATC CAGGCTGGGC AACAGAGTAA GATCCTGTAT 60CAAAAAGACC CCAAACCCCA ACACCAAACA GAGAAATGAA AATCAAACAA TATTTAGATT 120ACCTCCAATG ACTTCCCTGG CCCACACTCT TCATGTGTGC AGGTACTGGG GCTGTGCTGC 180CAGCAAGGTG TGCCCCTTCT GGAAAGGACG TCCATGGCCC TTGATGATTG TACCACACAC 240ACGGCCTGTG TCCTTGTCTA CTGGTTCTTG TGTGATAATC ACAGGGACAC CGATCATCCC 300TTTCGTCATG GACCCACAGC TGCAGGTGGA TTTCCATACC GAGATGAAGG AAGACTCAGA 360CATCGCCTTC CATTTCCGAG TGTACTTTGG TCATTGGGTG GTCATGAACA GCCGCGTGAA 420TGGGGCTTGG CAGTATGAGG TGACATGCCA CAATATGCCC TTTCAGGATG GTAAACCATT 480TAACCTGTGC ATCTCCGTGC TGGCCGATGA GTACCAGGTA ATGGTAAATG GCCAAAATGC 540TTACAGCTTT CCCCACCGAC TCCCACCATC TTATGTGAAG ATGGTGCAAG TGTGGAGAGA 600TGTCTCCCTG ACCTCAGTGT CTGTCTGTAA TTGATGAAAT GATCACATTC CTCATGGTTA 660AAGAATCCCT GTTTCTGTGC GACCATGGCA TTTCCAGAGC CTGCTAACAG AACGATC 717 ( 2 ) SEQ ID NO:12： ( ⅰ ) ：

(A) length: 168 amino acid

(B) type: amino acid

( D ) ： ( ⅱ ) ： ( ⅹⅰ ) ：SEQ ID NO:12Met Thr Ser Leu Ala His Thr Leu His Val Cys Arg Tyr Trp Gly 15Cys Ala Ala Ser Lys Val Cys Pro Phe Trp Lys Gly Arg Pro Trp 30Pro Leu Met Ile Val Pro His Thr Arg Pro Val Ser Leu Ser Thr 45Gly Ser Cys Val Ile Ile Thr Gly Thr Pro Ile Ile Pro Phe Val 60Met Asp Pro Gln Leu Gln Val Asp Phe His Thr Glu Met Lys Glu 75Asp Ser Asp Ile Ala Phe His Phe Arg Val Tyr Phe Gly His Trp 90Val Val Met Asn Ser Arg Val Asn Gly Ala Trp Gln Tyr Glu Val 105Thr Cys His Asn Met Pro Phe Gln Asp Gly Lys Pro Phe Asn Leu 120Cys Ile Ser Val Leu Ala Asp Glu Tyr Gln Val Met Val Asn Gly 135Gln Asn Ala Tyr Ser Phe Pro His Arg Leu Pro Pro Ser Tyr Val 150Lys Met Val Gln Val Trp Arg Asp Val Ser Leu Thr Ser Val Ser 165Val Cys Asn 168 ( 2 ) SEQ ID NO:13 ( ⅰ )

(A) length: 30 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:13:CAAGGTCGAC ATGACTTCCC TGGCCCACAC 30 (2) SEQ ID NO:14

(A) length: 30 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: SEQ ID NO:14CAAGAAGCTT ATGACTTCCC TGGCCCACAC 30

Claims (10)

1. isolated dna molecular is characterized in that it comprises: coding has the nucleotide sequence of the polypeptide of people CLC3 protein-active,

From the nucleotide sequence of Nucleotide 28-447 position or SEQID NO.11, show at least 70% homology among described nucleotide sequence and the SEQ ID NO.3 from the nucleotides sequence of Nucleotide 128-634 position; Perhaps

Described nucleotide sequence can be under the moderate stringent condition with SEQ ID NO.3 in from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11 from the nucleotide sequence hybridization of Nucleotide 128-634 position.

2. dna molecular as claimed in claim 1 is characterized in that, described sequence encoding one polypeptide, and this polypeptide has the sequence shown in SEQ ID NO:4 or 12.

3. dna molecular as claimed in claim 1 is characterized in that, this sequence has among the SEQ ID NO.3 from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11 the nucleotide sequence from Nucleotide 128-634 position.

4. an isolating people CLC3 protein polypeptide is characterized in that it comprises: polypeptide or its conservative property variation polypeptide or its active fragments or its reactive derivative with SEQ ID NO:4 or 12 aminoacid sequences.

5. polypeptide as claimed in claim 4 is characterized in that, this polypeptide is to have SEQ ID NO:4 or 12 polypeptide of sequence.

6. a carrier is characterized in that, it contains the described DNA of claim 1.

7. one kind with the described carrier transformed host cells of claim 6.

8. a generation has the method for the polypeptide of people CLC3 protein-active, it is characterized in that this method comprises:

(a) nucleotide sequence that coding is had a polypeptide of people CLC3 protein-active operationally is connected in expression regulation sequence, form people CLC3 protein expression vector, from the nucleotide sequence of Nucleotide 28-447 position or SEQ ID NO.11, show at least 70% homology among described nucleotide sequence and the SEQ ID NO.3 from the nucleotides sequence of Nucleotide 128-634 position;

(b) change the expression vector in the step (a) over to host cell, form the proteic reconstitution cell of people CLC3;

(c) under the condition that is fit to expressing human CLC3 protein polypeptide, the reconstitution cell in the culturing step (b);

(d) isolate polypeptide with people CLC3 protein-active.

9. energy and the described people CLC3 of claim 4 protein polypeptide specificity bonded antibody.

10. a probe molecule is characterized in that, it contains 8-100 continuous nucleotide in the described dna molecular of claim 1.

Images